BRIEF—Marinomed signs deal with Link Health Pharma

Austrian allergy, respiratory and eye disease specialist Marinomed Biotech has entered into a strategic partnership with China’s Link Health Pharma.

Link Health will take over the registration and distribution of Marinosolv products in China, making an upfront payment of 3 million euros ($3.4 million) plus milestone payments in the low double-digit million euro range per product.

Marinomed has also announced that the European Investment Bank (EIB) has approved a research project providing the company with 15 million euros for R&D.

Chief executive Andreas Grassauer said: "With our innovative technology platform Marinosolv we plan to enter the multi-billion dollar market for the treatment of allergies and eye diseases.”